How to reach Elan Pharmaceuticals, Inc.
Description
Elan Corporation; plc is a neuroscience-based biotechnology company that is focused on discovering; developing; manufacturing and marketing advanced therapies in neurology; autoimmune diseases; and severe pain. On June 5; 2006; Elan and Biogen Idec announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for the reintroduction of TYSABRI as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses. Tysabri will be available upon the completion of key activities related to the risk management plan; including FDA review of educational and training materials; internal validation of systems based on final FDA requirements and training of internal personnel. As such; the companies anticipate Tysabri will be available in July 2006. (ziconotide intrathecal infusion) for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted; and who are intolerant of or refractory to other treatment; such as systemic analgesics; adjunctive therapies or IT morphine. PRIALT is approved for use only in the Medtronic SynchroMed
Elan Pharmaceuticals, Inc. Contacts email addresses & email formats
Discover specific contacts and email addresses at Elan Pharmaceuticals, Inc..
Request a full profile of Elan Pharmaceuticals, Inc. with decision maker contacts and email address:
